Bmi1 Regulates Stem Cells and Proliferation and Differentiation of Committed Cells in Mammary Epithelium  by Pietersen, Alexandra M. et al.
Current Biology 18, 1094–1099, July 22, 2008 ª2008 Elsevier Ltd All rights reserved DOI 10.1016/j.cub.2008.06.070
Report
Bmi1 Regulates Stem Cells
and Proliferation and Differentiation
of Committed Cells in Mammary EpitheliumAlexandra M. Pietersen,1,3 Bastiaan Evers,2
Asheeta A. Prasad,1 Ellen Tanger,1
Paulien Cornelissen-Steijger,1 Jos Jonkers,2
and Maarten van Lohuizen1,*
1Division of Molecular Genetics
2Division of Molecular Biology
The Netherlands Cancer Institute
1066 CX Amsterdam
The Netherlands
Summary
PolycombGroup (PcG) proteins are epigenetic silencers
involved in maintaining cellular identity, and their deregula-
tion can result in cancer [1]. Mice without the PcG geneBmi1
are runted and suffer fromprogressive loss of hematopoietic
and neural stem cells [2–4]. Here, we assess the effects of
Bmi1 on stem cells and differentiation of an epithelial tissue
in vivo. We chose the mammary gland because it allows lim-
iting dilution transplantations [5, 6] and because Bmi1 is
overexpressed in breast cancer [7, 8]. Our analyses show
that Bmi1 is expressed in all cells of the mouse mammary
gland and is especially high in luminal cells. Loss of Bmi1 re-
sults in a severe mammary-epithelium growth defect, which
can be rescued by codeletion of the Ink4a/Arf locus or preg-
nancy. Even though mammary stem cells are present in the
absence of Bmi1, their activity is reduced, and this is only
partially due to Ink4a/Arf expression. Interestingly, loss
of Bmi1 causes premature lobuloalveolar differentiation,
whereas overexpression of Bmi1 inhibits lobuloalveolar
differentiation induced by pregnancy hormones. Because
Bmi1 affects not only mammary stem cells but also more
committed cells, our data warrant a more detailed analysis
of the different roles of Bmi1 in breast-cancer etiology.
Results and Discussion
Impaired Mammary-Gland Development
in Bmi1-Knockout Mice
To evaluate the role of Bmi1 in mammary epithelium, we com-
pared mammary glands from Bmi12/2 mice with those of their
wild-type littermates by whole-mount analysis. At 5 weeks
postpartum, mammary ducts in wild-type mice have started
to colonize the fat pad under the influence of pubertal hor-
mones. By this age the mammary glands exhibit Terminal
End Buds (TEBs), containing stem cells and their highly prolif-
erative progeny [9], that have extended beyond the lymph no-
des (Figure 1A, left panel). In contrast, the development of the
mammary gland in Bmi12/2 littermates was severely inhibited
(Figure 1A, right panel). Only occasionally did we observe an
isolated TEB in a Bmi12/2 mammary gland. In general, the
Bmi1-deficient ductal epithelium failed to invade the fat pad
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laid down during embryogenesis, indicating that Bmi1 plays
an essential role in postnatal mammary development. Histo-
logical analysis of the Bmi12/2 mammary glands demon-
strated that the mammary architecture remains intact, i.e.,
the mammary ducts consist of a single layer of luminal cells
surrounded by a layer of myoepithelial cells (Figure 1B). This
suggests that Bmi1 is not required to establish the fate of
these cells. Immunostaining of wild-type mammary glands
showed that Bmi1 expression is not restricted to a minority
of the epithelial cells, as might be expected from a protein
best known for its role in stem cells, but instead Bmi1 expres-
sion can be detected in all cells. Overall, Bmi1 expression is
variable in TEBs, low in the myoepithelium, and highest in
the luminal compartment (Figure 1B and Figure S1 available
online).
To determine whether the growth defect of Bmi12/2 mam-
mary glands is due to a defect in the epithelial cells or caused
by a deficiency in the environment of the cells, we isolated
Bmi12/2 mammary epithelial cells (MECs), briefly expanded
them in culture, and transplanted them into wild-type mice.
When 100,000 MECs lacking Bmi1 were injected into cleared
fat pads of wild-type mice, they still displayed a severe
growth defect 10 weeks after transplantation, in contrast to
wild-type cells that were injected contralaterally. To exclude
possible artifacts from the in vitro culture, we repeated this
experiment by transplanting a small piece of mammary tissue
from the Bmi12/2 mice from the nipple area directly into the
cleared fat pad of a wild-type mouse. Even though mammary
epithelium was detectable upon transplantation, there was
virtually no growth of the Bmi1-deficient tissue in contrast
to wild-type tissue, demonstrating that Bmi1 expression in
mammary epithelial cells is required for their proliferation
(Figure 1C).
Several, but not all, defects of Bmi12/2 mice are caused
by inappropriate Ink4a/Arf expression [10, 11]. p16Ink4a and
p19Arf, which induce cell-cycle arrest and apoptosis through
activation of Rb and p53, respectively, are not expressed in
normal tissue but induced upon oncogenic signaling [12, 13].
In mammary epithelium, repression of the Ink4a/Arf locus is
also dependent on Bmi1 because we found that the tran-
scripts of both Ink4a and Arf are increased in Bmi12/2
MECs compared to wild-type MECs (Figure S2, bars on
the left, labeled ‘‘virgin’’). When we codeleted the Ink4a/Arf
locus together with Bmi1 and transplanted this Bmi1;Ink4a/
Arf-deficient mammary tissue and cells, we found an almost
complete rescue of mammary growth (Figure 1D). This
demonstrates that the lack of repression of the Ink4a/Arf lo-
cus is mostly responsible for the growth defect of Bmi12/2
tissue.
Because growth defects in mammary-gland development
can often be rescued by pregnancy [14, 15], we tested this
for Bmi12/2 breast tissue as well. Because of the ill health
of the Bmi1-knockout mice, we used transplanted Bmi12/2
tissue pieces in wild-type mice, which we mated with males
4 weeks after transplantation. Interestingly, we observed
a near-complete rescue of Bmi1-deficient mammary
outgrowth during pregnancy (Figure 2A). We hypothesized
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activate multiple pathways that result in inhibition of the
cell-growth inhibitors p16Ink4a and p19Arf. To test this, we iso-
lated mammary epithelial cells from pregnant recipients that
had been previously transplanted with wild-type and Bmi12/2
tissue and determined the expression of Ink4a and Arf.
Surprisingly, Ink4a and Arf RNA and protein levels were still
high in Bmi1-deficient tissue (Figure S2 and Figure 2B), even
though there is extensive proliferation in these transplants
(Figure S2C). Apparently, pregnancy hormones overcome
the effects of these cell-cycle inhibitors to allow cell-cycle
progression, possibly through induction of cyclin D1 [16–18].
During pregnancy, lobules of alveolar cells are formed and
differentiate to become sites of milk production, a process
termed lobuloalveolar differentiation [9]. In pregnant recipi-
ents, this process occurs in the Bmi1-deficient outgrowths
that are indistinguishable from the contralateral wild-type con-
trol transplants, as judged by morphology and histology. In ad-
dition, one of the constituents of milk, b-casein, is induced to
Figure 1. Bmi1-Knockout Mice Show a Severe Defect in
Mammary Development
(A) Carmine-stained inguinal mammary glands from FVB
littermates, 38 days old, wild-type (WT) or knockout
(BmiKO) for Bmi1. ‘‘LN’’ stands for lymph node. Data
are represented as mean 6 SD, n = 4 glands per condi-
tion (30 to 40 days old).
(B) Immunohistochemistry on mammary glands from 5-
week-old wild-type and Bmi1-knockout mice (top and
bottom panel, respectively). There is no Bmi1 staining
in theBmi1-knockout mouse, as expected. Myoepithelial
(smooth muscle actin [SMA]) and luminal (E-cadherin)
cells are present and properly organized (H&E) in Bmi1-
knockout mammary glands.
(C) Five Bmi12/2 tissue pieces and two cell isolations
were injected into cleared fat pads of 21-day-old wild-
type recipients, and the outgrowth capacity was
analyzed 10 weeks later. The site of injection of the
wild-type tissue is indicated by an arrowhead. Seven
glands per genotype were analyzed from four indepen-
dent donor pairs (littermates).
(D) Five tissue transplants and three cell transplants of
Bmi1/Ink4a/Arf-deficient mammary glands were per-
formed. As a control, Ink4a/Arf2/2 mammary tissue or
cells were each time transplanted on the contralateral
side. The sites of injection are indicated by arrowheads.
Eight glands per genotype were analyzed (donor material
from six independent littermate pairs). The scale bars
represent 1 mm in (A, C, and D) and 50 mm in (B).
comparable levels in transplants of Bmi1-defi-
cient breast tissue and wild-type transplants
(Figure 3C), indicating that the Bmi1-deficient
mammary tissue is undergoing functional
differentiation as well. This suggests that preg-
nancy can override the block in proliferation
due to the absence of Bmi1, and Bmi1 is not
required for lobuloalveolar differentiation.
Loss of Bmi1 Affects Both Mammary Stem
Cells and Progenitors
The complete reconstitution of a mammary
tree in pregnant recipients illustrates that
mammary stem cells are present in the rudi-
mentary mammary structures observed in
the Bmi12/2 mouse. To obtain a quantitative
measurement of the effect of Bmi1 loss in mammary stem
cells in vivo, we performed limiting dilution transplantations.
First, we transplanted Bmi12/2 tissue and wild-type tissue
as a control into wild-type recipients. After rescuing the
Bmi12/2 growth by pregnancy, we harvested these cells for
use in a limiting dilution series in new recipients to analyze
the minimum number of cells required for growth of mam-
mary epithelial tissue; this number serves as an indication
of the amount of stem cells that were present in the original
cell isolate ([6], see Figure S3 for experimental set-up).
When half a million cells are injected and the recipient is
made pregnant, both wild-type and Bmi1-deficient cells are
capable of reconstituting a mammary gland (Figure S4A).
Upon reduction of the amount of injected cells, however, it
becomes apparent that there is a 14-fold reduction in mam-
mary repopulating units (MRUs) derived from the Bmi12/2
mammary gland (Table 1). Apparently, mammary stem cells
are less dependent on Bmi1 than for instance hematopoietic
stem cells [2, 3, 19].
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stem cell activity in Bmi1-deficient mammary cells, we com-
pared MECs with or without Bmi1 in the absence of the
Ink4a/Arf locus. Also in this case, we first transplanted Bmi1/
Ink4a/Arf-deficient tissue and Ink4a/Arf-deficient tissue as
a control into wild-type recipients to obtain sufficient cells
for the limiting dilution (Figure 1D and Figure S3). Loss
of Ink4a/Arf by itself does not affect the repopulation activity
(Table 1), suggesting that Ink4a/Arf levels in wild-type stem
cells are negligible. However, in Bmi1’s absence, which results
in derepression of the Ink4a/Arf locus, deletion of Ink4a/Arf
does have an effect on stem cell activity, albeit partial (3-fold
reduced compared to wild-type or Ink4a/Arf2/2 cell isolates,
Table 1). Importantly, the frequency of MRU remains similar
in pregnant and virgin recipients (compare wild-types with
Ink4a/Arf2/2, Table 1), consistent with previous reports dem-
onstrating an increase in stem cells accompanying the in-
crease in overall cell number during pregnancy [20]. Because
we measure functional stem cell activity, we can not gauge
the relative contribution of pregnancy-induced stem cells
[21], but our data demonstrate that there is an overall reduction
in stem cell frequency in the absence of Bmi1. Because the
rescue upon codeletion of the Ink4a/Arf locus was incomplete,
it is likely that Bmi1 is required to repress additional target
genes for the maintenance of mammary stem cells. Future
studies should elucidate whether these target genes are addi-
tional cell-cycle regulators such as p21 [22] or whether they
belong to the class of developmental regulators that are bound
by PcG in ES cells [23].
The fact that injections of high numbers of Bmi1-deficient
MECs, containing multiple mammary stem cells, did not show
any growth upon transplantation (Figure 1C) suggests that pro-
liferation of mammary progenitor cells is also hampered by the
absence of Bmi1. In contrast, loss of hematopoietic stem cells
in the Bmi1-deficient mouse is initially compensated by in-
creased proliferation of their immediate descendants [3].
Figure 2. Pregnancy Rescues Bmi1-Deficient Mammary
Outgrowth
(A) Four tissue pieces and three cell isolates of wild-type
and Bmi12/2 mammary glands were transplanted, and
the capacity to reconstitute a cleared fat pad was ana-
lyzed after 15–18 days pregnancy of the wild-type recip-
ients. The sites of injection are indicated by arrowheads.
Seven glands per genotype were quantified (donor mate-
rial from seven littermate pairs).
(B) MECs were isolated from two late-pregnant hosts (M1
and M2) that had been grafted with Bmi12/2 (KO) and
wild-type (WT) mammary tissue. Protein lysates were
probed for Ink4a and subsequently for Arf expression
(asterisk indicates Ink4a signal from first incubation; Arf
signal is marked by the arrowhead).
(C) Carmine staining of mammary glands from a 15-day-
pregnant wild-type recipient that was transplanted with
wild-type and Bmi12/2 mammary tissue reveals equal
lobuloalveolar morphology. mRNA levels of b-casein
are measured by Q-PCR and normalized against beta-
actin. Values are the mean of three independent MEC
isolations per genotype. The scale bars represent 1 mm.
Furthermore, Molofsky et al. showed that neu-
ral progenitors from the forebrain proliferate
normally in the absence of Bmi1 [4], although
granule cell precursor cells require Bmi1 for
their proliferation [24]. These data indicate
that not all progenitors are equally dependent on Bmi1 expres-
sion for their proliferation. There may be a tissue-specific de-
pendency on silencing of PcG targets such as the Ink4a/Arf lo-
cus, which in certain circumstances might not be activated, or
the function of Ink4a and Arf may be overruled downstream,
thereby alleviating dependence on Bmi1 for proliferation. This
is illustrated by our observation that pregnancy induces prolif-
eration in the mammary gland, regardless of high Ink4a and Arf
expression.
In vitro studies have suggested that in breast epithelium, like
in neural cells, Bmi1 is a downstream effector of sonic hedge-
hog (Shh) signaling and is required for mammary stem cells
[25]. In those studies, nonadherent cultures of human MECs,
termed mammospheres, are used as a measurement for stem
cell and progenitor activity. However, a recent publication
showed that even though Shh activation in mouse MECs like-
wise increases the number of mammospheres, there is an
actual reduction in the number of cells that are capable of
reconstituting the mammary gland [26]. Therefore, the authors
suggest that the mammosphere assay measures proliferation
and anchorage-independent growth rather than stem cell
activity. Our in vivo data demonstrate that loss of Bmi1 has an
effect on mammary stem cell activity but is also required
for proliferation of all progeny. Thus, the effect of Bmi1 loss
in mammospheres probably reflects both functions of
Bmi1: a partial loss of stem cell activity as well as a block in
proliferation.
Bmi1 Prevents Premature Initiation
of Lobuloalveolar Differentiation
Upon close examination, Bmi12/2 mammary tissue showed
morphological signs of lobuloalveolar differentiation when it
was transplanted into the fat pad of a virgin recipient. This sug-
gests that without Bmi1, mammary cells may enter premature
differentiation (Figure 3A). To further define this morphological
phenotype in the Bmi1-deficient transplants, we used two
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pregnant tissue, NKCC1 and Npt2b, respectively [27]. In the
transplants of Bmi12/2breast tissue, some ducts showed a vir-
gin-like expression of NKCC1 (data not shown), but other
structures have lost such NKCC1 staining, similar to pregnant
tissue (Figure 3B).
The Na-Pi type IIb cotransporter (Npt2b) is not detectable in
virgin tissue, but becomes expressed at the apical membrane
from day 15 of pregnancy and remains present during lacta-
tion. Strikingly, in the Bmi1-deficient transplants more than
Figure 3. Loss of Bmi1 Facilitates Lobuloalveolar Differenti-
ation
(A) Carmine-stained wholemount analysis. During preg-
nancy, the ducts that have a smooth appearance in the
wild-type virgin mouse become lined with budding alveoli
(left and right panels). The limited outgrowths of Bmi12/2
transplants in virgin recipients form structures that morpho-
logically resemble alveoli (middle).
(B) Immunofluorescent staining on paraffin sections from
mammary glands as indicated. Luminal cells of virgin ducts
show clear membrane staining of the NKCC1 transporter
(left panel), whereas this expression is largely lost during
pregnancy (right panel). Several Bmi12/2 ducts transplanted
in virgin recipients have also lost NKCC1 staining (Tp
BmiKO). Conversely, the Npt2b transporter is not expressed
in virgin tissue (left panel) but becomes expressed at the lu-
men of alveoli during pregnancy (right panel). Almost half of
Bmi1-deficient mammary structures in virgin recipients ex-
hibit properly localized Npt2b staining (Tp BmiKO and [C]).
(C) The percentage of Npt2b-positive ducts in tissue sec-
tions of at least three independent transplantations (left
side) or three independent mammary glands (right side,
‘‘straight’’) was determined per genotype. The scale bars
represent 500 mm in (A) and 50 mm in (B).
Table 1. Mammary Stem Cell Activity Is Reduced in the Absence of Bmi1
Genotype MRU 6 SE Fold Reduction p Value
wild-type 1/1,984 1/1,369–1/2,875
Bmi12/2 1/26,728 1/19,358–1/36,905 13.5 0.0001
Ink4a/Arf2/2 1/2,032 1/1,409–1/2,929 1.0 0.9633
Bmi1/Ink4a/Arf2/2 1/6,486 1/4,788–1/8,786 3.3 0.0135
The frequency of mammary-gland repopulating units (MRUs) was deter-
mined by limiting dilution transplantations of Bmi12/2 and wild-type
MECs after rescue by pregnancy and for Bmi1/Ink4a/Arf and Ink4a/Arf-
deficient cells in virgin recipients. See Figures S3 and S4 for experimental
details. The fold reduction is relative to wild-type cells, and goodness
of fit to a single-hit Poisson model was tested with standard Chi-square
statistics.
half of the mammary structures expressed
Npt2b, indicating that this process is normally re-
pressed by Bmi1 in wild-type cells (Figures 3B and
3C). Interestingly, when transplants from Bmi1/
Ink4a/Arf-deficient tissue were stained for
Npt2b, the number of positive ducts was still in-
creased compared to wild-type or Ink4a/Arf2/2
transplants (Figure 3C). Since these cells are pro-
liferating and reconstituting a cleared fat pad, this
indicates that the precocious differentiation in the
absence of Bmi1 alone is not initiated by expres-
sion of Ink4a and Arf or a default response to
a block in proliferation. This suggests that Bmi1
generally prevents premature differentiation in
the virgin mammary gland through repression of genes other
than Ink4a and Arf.
To further substantiate the role of Bmi1 in lobuloalveolar dif-
ferentiation, we manipulated Bmi1 levels in HC11 cells. This
mouse mammary cell line can be induced to differentiate
when the cells have established cell-cell contacts upon conflu-
ency combined with the addition of lactogenic hormones
[28]. Functional differentiation can be subsequently quantified
by determining the expression of milk proteins, such as
b-casein [29]. Strikingly, knockdown of Bmi1 in HC11 cells
greatly increased the b-casein production upon differentiation
(Figure 4A). Conversely, overexpression of Bmi1 prevented
b-casein expression completely, comparable to HC11 cells
that have not been induced to differentiate (Figure 4B). This
observation predicts that Bmi1 should be downregulated dur-
ing pregnancy to allow efficient alveolar differentiation and
milk production. We isolated MECs from two independent
sets of mice at different stages of development and preg-
nancy. During the initial stages of pregnancy, Bmi1 levels are
upregulated, possibly related to the increased mammary cell
proliferation that occurs at this time. However, at later time
points we observed a significant decrease in Bmi1 levels,
especially during lactation and involution (Figure 4C).
In summary, a picture emerges whereby wild-type levels
of Bmi1 are required to prevent spurious activation of
Current Biology Vol 18 No 14
1098terminal differentiation, whereas overexpression of Bmi1
inhibits activation of this program, even in the presence of
the appropriate signals [30]. For instance, wild-type Bmi1
levels prevent Ink4a and Arf expression and thereby prema-
ture senescence. Upon oncogenic signaling such as consti-
tutive activation of c-Myc or Ras, the Ink4a/Arf locus is
expressed, which functions as a failsafe mechanism against
tumorigenesis [31]. Bmi1 overexpression, however, overrules
this tumor-suppressive response by hyperrepressing the
Ink4a/Arf locus [32]. Overall, Bmi1 levels seem to determine
the threshold for signals to activate its target genes. In the
mammary gland, Bmi1 fulfills this function not only on the
Ink4a/Arf locus, but also on (as-yet-unidentified) inducers
of alveolar differentiation. Whereas genome-wide mapping
of PcG targets in embryonic stem cells have already sug-
gested a role for PcG proteins in preventing differentiation
[23, 33], we now show for the first time that Bmi1 is function-
ally required for the prevention of premature differentiation
in more committed cells as well.
Implications for Breast Cancer
Several correlative studies implicate Bmi1 in breast cancer [7,
8], but it is unknown whether Bmi1 has a causal role in this ma-
lignancy and if so, what is the relative importance of Bmi1’s
roles in the mammary gland. As our data show, Bmi1 affects
mammary stem cells’ proliferation and differentiation. Liu
et al. observed that Bmi1 levels are increased in a subpopula-
tion of breast cancer cells, and this led to the speculation that
Bmi1 is involved in the self-renewal of cancer stem cells [25].
In addition, continuous overexpression of Bmi1 would be
expected to prevent the tumor-suppressive activity of both
Ink4a and Arf. A study by Yi et al. [34] suggested that loss of
Arf endows mammary cells with indefinite reconstitution ca-
pacity. Overexpression of Bmi1 could have an analogous
effect, namely prevention of Arf activation, thereby creating
immortal cells. Moreover, Bmi1 overexpression may contrib-
ute to the immortality of mammary cells via induction of telo-
merase [7]. In that respect, it would be interesting to assess
the serial transplantation capacity of Bmi1-overexpressing
Figure 4. High Bmi1 Levels Block Lobuloalveolar Differenti-
ation
(A) Knockdown of Bmi1 by two independent shRNAs (63%
and 85% reduction in mRNA levels for shRNA#1 and #2, re-
spectively) increases b-casein production in HC11 cells after
the addition of lactogenic hormones (DIP), relative to empty
vector (EV)-transduced cells.
(B) Bmi1 overexpression in HC11 cells represses b-casein
production after DIP (note the difference in scale). The
graphs in (A) and (B) show one experiment that is represen-
tative of three independent experiments.
(C) Western-blot analysis of Bmi1 protein levels at various
stages of wild-type mammary-gland development, as fol-
lows: virgin (V), 7, 15, and 19 days pregnant, 11 days lactating
(L), and 3 days after involution (I). Samples are representative
of two independent sets of MECs. Tubulin levels are shown
as a loading control.
MECs. Our current study provides yet another
possible contribution of Bmi1 overexpression to
breast cancer: Bmi1 overexpression might con-
tribute to an increase in the population of cells
that could be susceptible to oncogenic transfor-
mation by blocking terminal differentiation.
Together, our data demonstrate that Bmi1 is required for
mammary-gland development during puberty but not for alve-
olar differentiation during pregnancy. We show that mammary
stem cells are partially dependent on Bmi1 and that Bmi1 is re-
quired to allow proliferation of mammary epithelial cells and to
prevent premature differentiation. The relative contributions of
these functions of Bmi1 to its role in breast cancer will be the
focus of our future studies. In general, our data illustrate the
flexibility of epigenetic silencing by PcG proteins that cater
to the plasticity that is required for cell-fate regulation during
development and adult life.
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Supplemental Data include Supplemental Experimental Procedures, four
figures, and one table and can be found with this article online at http://
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